Loading...
XSTOBOUL
Market cap31mUSD
Dec 23, Last price  
9.00SEK
1D
1.35%
1Q
3.21%
Jan 2017
-87.14%
IPO
-22.08%
Name

Boule Diagnostics AB

Chart & Performance

D1W1MN
XSTO:BOUL chart
P/E
13.99
P/S
0.61
EPS
0.64
Div Yield, %
0.00%
Shrs. gr., 5y
7.21%
Rev. gr., 5y
6.13%
Revenues
571m
+4.24%
168,693,500175,391,166229,421,000246,155,000275,301,000276,804,000306,687,000331,407,000400,735,000427,793,000424,400,000498,916,000400,458,000463,344,000548,088,000571,329,000
Net income
25m
+96.24%
-5,549,061-10,548,23318,891,00011,711,00010,959,000-70,125,00030,265,00015,352,00036,033,00037,239,00041,031,00037,548,000-47,965,00023,272,00012,728,00024,977,000
CFO
51m
P
4,310,8948,203,59716,159,0005,444,00010,948,00015,675,00030,985,00022,324,00019,875,00057,715,00022,663,00053,976,00075,239,00043,284,000-11,353,00051,377,000
Dividend
May 06, 20220.38946 SEK/sh
Earnings
Feb 11, 2025

Profile

Boule Diagnostics AB (publ), a diagnostics company, develops, manufactures, and markets instruments and consumable products for blood diagnostics. The company provides hematology analyzers, reagents, blood controls and calibrators, and reagents rotors, as well as cleaning products under the Swelab, Medonic, and Quintus brands; and veterinary hematology and clinical chemistry analyzer and diagnostics systems under the Exigo brand. It sells its products directly in Sweden and the United States, as well as through distributors internationally. The company serves hospitals, clinics, laboratories, healthcare centers and veterinary clinics, and other diagnostics companies. It has operations in Sweden, the United States, Mexico, and Russia. The company was founded in 1956 and is headquartered in Spånga, Sweden.
URL
https://www.boule.com/
IPO date
Jun 23, 2011
Employees
200
Domiciled in
SE
Incorporated in
SE

Valuation

Title
SEK in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
571,329
4.24%
548,088
18.29%
463,344
15.70%
Cost of revenue
528,059
515,346
428,186
Unusual Expense (Income)
NOPBT
43,270
32,742
35,158
NOPBT Margin
7.57%
5.97%
7.59%
Operating Taxes
5,123
8,121
5,496
Tax Rate
11.84%
24.80%
15.63%
NOPAT
38,147
24,621
29,662
Net income
24,977
96.24%
12,728
-45.31%
23,272
-148.52%
Dividends
(10,679)
(10,679)
Dividend yield
2.48%
0.78%
Proceeds from repurchase of equity
(560)
123,799
BB yield
0.13%
-28.79%
Debt
Debt current
97,480
105,069
104,753
Long-term debt
92,600
121,102
78,322
Deferred revenue
Other long-term liabilities
8,317
3,133
3,899
Net debt
152,799
79,649
104,241
Cash flow
Cash from operating activities
51,377
(11,353)
43,284
CAPEX
(82,700)
(74,961)
(56,370)
Cash from investing activities
(82,714)
(74,961)
(56,370)
Cash from financing activities
(25,506)
140,550
15,754
FCF
56,896
(33,776)
33,993
Balance
Cash
37,281
96,904
38,183
Long term investments
49,618
40,651
Excess cash
8,715
119,118
55,667
Stockholders' equity
138,893
125,741
93,349
Invested Capital
640,871
524,508
388,231
ROIC
6.55%
5.39%
8.16%
ROCE
6.66%
5.02%
7.74%
EV
Common stock shares outstanding
38,833
28,477
28,172
Price
11.22
-25.70%
15.10
-69.06%
48.80
-17.98%
Market cap
435,706
1.33%
430,003
-68.72%
1,374,806
-15.74%
EV
588,505
509,652
1,479,047
EBITDA
67,885
59,917
56,636
EV/EBITDA
8.67
8.51
26.11
Interest
11,264
9,821
5,448
Interest/NOPBT
26.03%
30.00%
15.50%